Acquired cystic fibrosis transmembrane conductance regulator dysfunction
Catherine Banks, Laura Freeman, Do Yeon Cho and 1 more
World Journal of Otorhinolaryngology-Head and Neck Surgery · 2018
doi:10.1016/j.wjorl.2018.09.001 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Sinonasal respiratory epithelium is a highly regulated barrier that employs mucociliary clearance (MCC) as the airways first line of defense. The biological properties of the airway surface liquid (ASL), combined with coordinated ciliary beating, are critical components of the mucociliary apparatus. The ASL volume and viscosity is modulated, in part, by the cystic fibrosis transmembrane conductance regulator (CFTR). The CFTR is an anion transporter of chloride (Cl−) and bicarbonate (HCO3−) that is located on the apical surface of respiratory epithelium and exocrine glandular epithelium. Improved understanding of how dysfunction or deficiency of CFTR influences the disease process in both genetically defined cystic fibrosis (CF) and acquired conditions has provided further insight into potential avenues of treatment. This review discusses the latest data regarding acquired CFTR deficiency and use of CFTR specific treatment strategies for CRS and other chronic airway diseases. Keywords: CFTR, Cystic fibrosis, CFTR deficiency, CFTR dysfunction, Chronic sinusitis, Chronic rhinosinusitis, Chronic obstructive pulmonary disease, Tobacco, Hypoxia, Resveratrol, l-ascorbate
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.